Core Viewpoint - Eli Lilly and Company reported mixed first-quarter 2025 results, missing earnings estimates but exceeding revenue expectations, driven by strong sales of its diabetes and weight loss medications [1][2][13]. Financial Performance - Adjusted EPS for Q1 2025 was $3.34, missing the Zacks Consensus Estimate of $3.52, but representing a 29% year-over-year increase [1]. - Total revenues reached $12.73 billion, a 45% increase year-over-year, surpassing the Zacks Consensus Estimate of $12.62 billion [2]. Key Drug Sales - Mounjaro sales were $3.84 billion, up 113% year-over-year, exceeding the Zacks Consensus Estimate of $3.75 billion [3]. - Zepbound generated $2.31 billion in sales, compared to $1.91 billion in the previous quarter, beating the Zacks Consensus Estimate of $2.27 billion [4]. - Trulicity sales fell 25% year-over-year to $1.1 billion, aligning with the Zacks Consensus Estimate [6]. - Jardiance sales increased 48% to $1.01 billion, significantly surpassing the Zacks Consensus Estimate of $675 million [7]. - Taltz generated $761.9 million, up 30% year-over-year, beating the Zacks Consensus Estimate of $663 million [7]. - Verzenio sales were $1.16 billion, a 10% increase year-over-year, but missed the Zacks Consensus Estimate of $1.25 billion [8]. - Emgality revenues dropped 45% to $124.6 million, while Olumiant sales rose 5% to $228.7 million [9]. Guidance and Market Position - The company maintained its 2025 revenue guidance of $58.0 billion to $61.0 billion, indicating a 32% year-over-year growth, but lowered EPS guidance to $20.78 to $22.28 [11][12]. - Competition from Novo Nordisk's semaglutide products is significant, with expectations of strong revenue growth for Novo's offerings [5][16]. - Lilly is investing in obesity treatments and has new molecules in clinical development, including a promising oral GLP-1 agonist [16][18]. Market Reaction - Despite strong sales, Lilly's shares fell nearly 5% in pre-market trading due to the EPS miss and lowered earnings guidance [14]. - CVS Caremark's decision to exclude Zepbound from its preferred drug list may impact sales [14]. - Lilly's stock has increased 16.7% year-to-date, outperforming the industry average of 3.5% [14].

Thursday, May 1, 2025Pre-market futures are up this morning, though somewhat muted from levels prior to economic reports out this morning on unemployment claims. We also see a full compliment of Q1 earnings reports ahead of today’s opening bell, with another couple “Mag 7” companies due to report after today’s close. Jobless Claims Jump Higher Last WeekFor months, we’ve been talking in this space about the steadiness and resiliency of weekly unemployment claims. While other metrics on the economy and employ ...

Financial Performance - Revenue for the three months ended March 31, 2025, was $12,728.5 million, a 45% increase from $8,768.0 million in the same period of 2024[114] - Net income for the same period was $2,759.3 million, up 23% from $2,242.9 million year-over-year[114] - Earnings per share (diluted) increased to $3.06, a 23% rise compared to $2.48 in the prior year[114] - U.S. revenue increased by 49% to $8,489.4 million, while revenue outside the U.S. rose by 38% to $4,239.1 million[131] - Mounjaro revenue reached $3,841.8 million, a 113% increase from $1,806.5 million in the previous year[134] - Zepbound revenue in the U.S. was $2.31 billion, compared to $517.4 million in the same quarter of 2024, driven by increased demand[135] - Revenue of Verzenio increased 3 percent in the U.S. and 22 percent outside the U.S. during the three months ended March 31, 2025[136] - Gross margin for the three months ended March 31, 2025 was $10,504.3 million, a 48 percent increase from $7,094.5 million in 2024, with a gross margin percentage of 82.5%[137] Expenses and Investments - Research and development expenses rose 8 percent to $2,733.7 million, reflecting continued investments in the portfolio[138] - Marketing, selling, and administrative expenses increased 26 percent to $2,468.8 million, driven by promotional efforts for ongoing and future launches[139] Debt and Cash Management - Total debt increased to $38.52 billion as of March 31, 2025, up $4.87 billion from $33.64 billion as of December 31, 2024[148] - Cash and cash equivalents decreased to $3.09 billion as of March 31, 2025, compared to $3.27 billion as of December 31, 2024[145] - The company repurchased $1.20 billion of shares during the three months ended March 31, 2025, with $13.80 billion remaining under the share repurchase program[150] - The company has $8.42 billion of unused committed bank credit facilities, with $8.00 billion available to support the commercial paper program[149] Regulatory and Market Challenges - The company withdrew its U.S. application for tirzepatide for heart failure with preserved ejection fraction in 2025[116] - The European Medicines Agency did not recommend donanemab for approval for early symptomatic Alzheimer's disease, and the company is seeking re-examination[116] - Jardiance was selected for government-set prices effective in 2026, which may influence future business strategies[118] - The company continues to face challenges from regulatory scrutiny and potential tariffs that could impact operations and costs[120] Taxation - The effective tax rate increased to 20.2 percent for the three months ended March 31, 2025, compared to 11.6 percent in 2024[140] Future Commitments - The company expects to incur up to approximately $8 billion in payments related to executed agreements for contract manufacturing and supply of materials over the next several years[144]

For the quarter ended March 2025, Eli Lilly (LLY) reported revenue of $12.73 billion, up 45.2% over the same period last year. EPS came in at $3.34, compared to $2.58 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $12.62 billion, representing a surprise of +0.86%. The company delivered an EPS surprise of -5.11%, with the consensus EPS estimate being $3.52.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Eli Lilly (LLY) Q1 2025 Earnings Call May 01, 2025 10:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Later, we will be conducting a question and answer session and instructions will be given at that time. I would now like to turn the conference over to your host, Mike Senior Vice President of Investor Relations. Please go ahead. Speaker1 Good morning. Thank yo ...

Eli Lilly (LLY) Q1 2025 Earnings Call May 01, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President Investor RelationsDavid Ricks - Chairman and Chief Executive OfficerLucas Montarce - Executive VP & CFODaniel Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunologyGeoff Meacham - Managing DirectorChris Schott - Managing DirectorPatrik Jonsson - EVP & President - Lilly Cardiometabolic Health & Lilly USAMohit Bansal - Managing DirectorAlex ...

CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City.Eli Lilly CEO Dave Ricks on Thursday said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. The Trump administration has opened a Section 232 investigation into how importing certain drugs into the U.S. affects national security – a move widely seen as a prelude to initiating tariffs on pharmaceuticals. It ...

Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.11%. A quarter ago, it was expected that this drugmaker would post earnings of $5.03 per share when it actually produced earnings of $5.32, delivering a surprise of 5.77%.Over the last four quarters, the company has su ...

Dave Ricks, Chair and Chief Executive Officer Q1 2025 Financial Results Lucas Montarce, Chief Financial Officer R&D Update Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer Q1 2025 EARNINGS CALL ELI LILLY AND COMPANY Agenda Introduction and Key Events Closing Remarks Dave Ricks, Chair and Chief Executive Officer Question & Answer Session 3 2025 Q1 EARNINGS Safe Harbor Provision and Other Information This presentation contains forward-looking statements that are based on management's current expectations ...

May 1, 2025 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; (317) 416-4363 (Media) Mike Czapar; czapar_michael_c@lilly.com; (317) 617-0983 (Investors) First-Quarter Reported Results In Q1 2025, worldwide revenue was $12.73 billion, an increase of 45% compared with Q1 2024, driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of foreign exchange rates. Key Products revenue grew by $4.09 billion to $7.52 ...